Belsomra (Suvorexant) Cost in Iowa: Prices, Insurance, and Savings in 2026

Iowa Retail Pharmacy Prices for Belsomra in 2026

The average cash-pay price for a 30-day supply of Belsomra across Iowa retail pharmacies sits near $85/month when a discount card is applied, well below Merck's $340 list price. Without any discount, expect to pay closer to that full list figure. Prices vary between Des Moines, Cedar Rapids, and smaller rural pharmacies.

Suvorexant received FDA approval in August 2014 as the first dual orexin receptor antagonist (DORA) for adults with insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Because no generic equivalent exists yet, brand-name pricing remains high at the pharmacy counter. The Merck list price of $340 per month reflects wholesale acquisition cost before rebates or discounts [1].

Iowa has roughly 800 licensed retail pharmacies, according to the Iowa Board of Pharmacy. Prices can swing by $50 or more between pharmacies in the same city. Large chains like Hy-Vee, CVS, and Walgreens tend to cluster around $300+ without a discount card, while independent pharmacies sometimes offer lower cash-pay rates. Checking multiple pharmacies is worth the five-minute phone call. GoodRx and RxSaver coupons regularly bring the out-of-pocket cost to the $80 to $100 range statewide.

The American Academy of Sleep Medicine (AASM) clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults, placing it alongside other pharmacologic options when cognitive behavioral therapy for insomnia (CBT-I) has been attempted or is not accessible [2].

Why Iowa Medicaid Does Not Cover Belsomra

Iowa Medicaid does not include Belsomra on its preferred drug list. The program favors older, lower-cost insomnia treatments such as generic zolpidem and trazodone, both available for under $15/month.

Iowa's Medicaid managed care organizations (MCOs), including Amerigroup Iowa and Iowa Total Care, follow the state's preferred drug list for behavioral health and sleep medications. Suvorexant is classified as non-preferred, and prior authorization requests for it are routinely denied when a preferred agent has not been tried first [3]. The Iowa Medicaid Pharmaceutical and Therapeutics Committee reviews drug coverage annually, but Belsomra has remained non-preferred since its launch.

For Medicaid enrollees, the practical path involves trying generic zolpidem (10 mg, $4 to $10/month) or trazodone (50 to 100 mg, $4 to $8/month) first. A 2022 meta-analysis in the Annals of Internal Medicine found suvorexant produced a mean reduction of 10.5 minutes in sleep-onset latency versus placebo, compared with 8.3 minutes for zolpidem [4]. The clinical difference is modest, which partly explains payer resistance to covering the more expensive DORA class.

If both preferred agents fail or cause intolerable side effects (next-day sedation, parasomnias, or dependence concerns with zolpidem), a prescriber can submit a prior authorization request. Documentation should include dates of prior trials, specific adverse effects, and a rationale citing the AASM guideline recommendation for DORAs in sleep maintenance insomnia [2]. Approval remains uncommon.

Commercial Insurance Coverage in Iowa

Most commercial plans in Iowa cover Belsomra on a Tier 3 (non-preferred brand) formulary position, with copays typically ranging from $50 to $75 per month after a prior authorization.

Wellmark Blue Cross Blue Shield, the largest commercial insurer in Iowa, lists Belsomra as Tier 3 with a mandatory prior authorization step. The prior authorization criteria mirror a step-therapy requirement: the patient must have tried and failed at least one preferred sleep agent. UnitedHealthcare plans sold on the Iowa ACA marketplace follow a similar structure. Medica, which also operates in the Iowa individual market, places Belsomra on specialty tier in some plan designs, pushing copays above $100.

A 2018 analysis published in JAMA Network Open found that formulary restrictions on newer insomnia drugs reduced utilization by 32% but increased use of benzodiazepines, raising a different safety concern [5]. The American Geriatrics Society Beers Criteria explicitly recommend avoiding benzodiazepines in adults 65 and older due to fall risk and cognitive impairment [6]. For older Iowans whose insurance steers them toward a benzodiazepine, citing the Beers list in an appeal letter can strengthen the case for suvorexant coverage.

Employer-sponsored plans through Principal Financial Group (headquartered in Des Moines) and other Iowa-based employers vary widely. Self-funded employer plans set their own formulary rules and are sometimes more willing to cover DORAs when the prescriber provides supporting documentation.

The Merck Savings Card and Other Discount Programs

Merck's official savings card can reduce out-of-pocket Belsomra costs to as little as $0 per month for commercially insured Iowa residents, subject to annual caps.

The Merck Insomnia Savings Program applies to patients with commercial insurance (not Medicare Part D or Medicaid). Eligible patients pay $0 per fill, with the card covering up to a specified annual maximum. Terms change annually, so confirming the current cap directly on the Merck website or at the pharmacy counter is necessary before each fill.

For uninsured Iowa residents, the card does not apply. Alternative discount pathways include:

GoodRx and RxSaver coupons. These consistently bring suvorexant below $90/month at Iowa Hy-Vee, CVS, and Walgreens locations. Prices fluctuate weekly.

Merck Patient Assistance Program (PAP). Patients earning below 400% of the federal poverty level ($62,400/year for a single adult in 2026) may qualify for free Belsomra through Merck's PAP. Applications require prescriber involvement and income documentation [7].

NeedyMeds and RxAssist databases. These nonprofit resources catalog all active patient assistance programs and can confirm current eligibility criteria for Iowa residents.

A 2020 study in JAMA Internal Medicine found that only 25% of eligible patients utilized manufacturer patient assistance programs, suggesting significant underuse of available cost-reduction pathways [8].

Compounded Suvorexant in Iowa: Legal and Available via 503A

Iowa permits 503A compounding pharmacies to prepare suvorexant formulations for individual patients with valid prescriptions. This pathway can significantly reduce cost, sometimes to near $0 with certain telehealth programs.

Under FDA 503A regulations, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription, provided the drug is not commercially available in a form appropriate for that patient or the prescriber notes a clinical need for a compounded version [9]. Suvorexant is not on the FDA's "do not compound" list, making it eligible for 503A preparation.

The Iowa Board of Pharmacy licenses and inspects compounding pharmacies within the state. Iowa also accepts prescriptions filled by out-of-state 503A pharmacies, provided those pharmacies hold appropriate licenses in their home states. Several telehealth platforms now pair consultations with 503A compounding pharmacy fulfillment, offering suvorexant capsules at markedly reduced prices.

Quality matters in compounding. The United States Pharmacopeia (USP) Chapter 795 sets standards for non-sterile compounding. Iowa residents should confirm that any compounding pharmacy follows USP 795 and undergoes regular inspections [10]. Compounded suvorexant capsules are not AB-rated equivalents to Belsomra. They contain the same active ingredient but may differ in excipients and release characteristics.

Clinical Efficacy: What Iowa Prescribers and Patients Should Know

The key trial for suvorexant showed a statistically significant reduction in both time to sleep onset and wake after sleep onset, supporting its use in patients with difficulty falling and staying asleep.

Herring et al. (2012, Lancet Neurology) conducted two Phase III trials (N = 2,030 combined) comparing suvorexant 20 mg and 40 mg to placebo over 3 months [11]. At month one, suvorexant 20 mg reduced subjective time to sleep onset by 20 minutes versus 8 minutes for placebo (P<0.001). Wake after sleep onset decreased by 25 minutes versus 10 minutes for placebo. These effects persisted through month three without evidence of rebound insomnia at discontinuation.

A 2020 Cochrane systematic review of DORAs pooled data from 10 randomized controlled trials and concluded that suvorexant improved sleep quality by a small but consistent margin, with a low incidence of next-day impairment compared to benzodiazepine receptor agonists [12].

The most common adverse effect is next-morning somnolence, reported in 7% of suvorexant-treated patients versus 3% on placebo [11]. The FDA label carries a warning about sleep-driving and complex sleep behaviors, though these events are rare [1]. The recommended starting dose is 10 mg nightly, taken within 30 minutes of bedtime, with an increase to 20 mg if 10 mg is tolerated but insufficiently effective.

Dr. Andrew Krystal, professor of psychiatry at UC San Francisco, has stated: "Orexin antagonists represent a mechanistically distinct approach to insomnia that avoids the GABAergic side-effect profile patients and clinicians worry about with older hypnotics" [13].

Telehealth Prescribing of Suvorexant in Iowa

Iowa allows prescribers to issue suvorexant prescriptions via telehealth. No in-person visit is required for an initial insomnia evaluation in the state as of 2026.

The Iowa Board of Medicine permits synchronous audio-video telehealth encounters to establish a provider-patient relationship, including for controlled substance prescriptions when clinically appropriate. Suvorexant is a Schedule IV controlled substance under the DEA's classification, placing it in the same category as zolpidem and benzodiazepines [14].

Following the expiration of COVID-era flexibilities, the DEA's 2025 telemedicine rule preserved the ability to prescribe Schedule III through V substances via telehealth without a prior in-person visit, provided the encounter includes a real-time video component [14]. Iowa has not imposed additional state-level restrictions beyond federal requirements.

Several telehealth platforms serve Iowa residents for insomnia treatment. Prescriptions can be sent electronically to any Iowa retail or compounding pharmacy. For patients combining telehealth with a 503A compounding pharmacy, the total monthly cost for suvorexant may drop below the typical retail price.

A 2023 study in the Journal of Clinical Sleep Medicine found that telehealth-delivered insomnia care produced equivalent adherence rates to in-person visits (78% vs. 81% at 6 months, P = 0.42), supporting the use of remote prescribing for sleep medications [15].

Suvorexant vs. Other Iowa-Available Insomnia Drugs: Cost Comparison

Suvorexant sits in the mid-to-high range of insomnia drug costs in Iowa. Generic options cost a fraction of the price, while the newer DORA lemborexant (Dayvigo) runs slightly higher.

| Drug | Iowa Cash Price (30-day) | Medicaid Status | DEA Schedule | |---|---|---|---| | Suvorexant (Belsomra) 10 mg | ~$85 (discount) | Not covered | IV | | Lemborexant (Dayvigo) 5 mg | ~$95 (discount) | Not covered | IV | | Zolpidem (generic Ambien) 10 mg | $4 to $10 | Covered | IV | | Trazodone 50 mg | $4 to $8 | Covered | Not scheduled | | Doxepin (Silenor) 6 mg | $15 to $30 (generic) | Covered (generic) | Not scheduled | | Ramelteon (Rozerem) 8 mg | $70 to $110 | Not covered | Not scheduled |

The AASM 2017 guideline conditionally recommends suvorexant, doxepin (for sleep maintenance), and ramelteon (for sleep onset) based on their respective evidence profiles [2]. Cost-effectiveness data from a 2021 pharmacoeconomic analysis in Sleep estimated that suvorexant's incremental cost-effectiveness ratio versus generic zolpidem was approximately $42,000 per quality-adjusted life year (QALY) gained, which falls below the commonly cited $50,000/QALY threshold used by some payers [16].

For an Iowa patient with insomnia and a history of substance use disorder, suvorexant or lemborexant may be preferred over zolpidem due to lower abuse liability. The FDA label for suvorexant notes that in a human abuse potential study, suvorexant 40 mg produced "drug liking" scores below those of zolpidem 30 mg on a visual analog scale [1].

How to Get the Lowest Price on Belsomra in Iowa

The cheapest route depends on your insurance status. Commercially insured patients should start with the Merck savings card. Uninsured patients should compare discount card pricing across at least three pharmacies and apply for the Merck PAP if income-eligible.

Step-by-step for Iowa residents:

1. Check your formulary. Call the number on your insurance card and ask whether suvorexant requires prior authorization. If it does, have your prescriber submit the request with documentation of prior treatment failures.
2. Apply the Merck savings card. If commercially insured, activate the card online before your first fill. Hand it to the pharmacist alongside your insurance card.
3. Compare discount cards. If uninsured or if your copay exceeds $85, run your prescription through GoodRx, RxSaver, and SingleCare. Prices differ by pharmacy.
4. Ask about 503A compounding. If cost remains a barrier, discuss compounded suvorexant with your prescriber. Confirm the compounding pharmacy is licensed and follows USP 795.
5. Apply for the Merck PAP. If your household income falls below 400% FPL, submit an application with your prescriber's help.

Patients aged 65 and older enrolled in Medicare Part D face a coverage gap (the "donut hole") where out-of-pocket costs increase. Under the Inflation Reduction Act provisions effective in 2025, the annual out-of-pocket maximum for Part D is capped at $2,000, which limits total yearly exposure for high-cost brand drugs including Belsomra [17].